Compare LYFT Inc (LYFT) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Smith & Nephew plc — how do they compare? LYFT Inc trades at $16.16 (market cap $6.11B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while LYFT Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 47 Days and Smith & Nephew plc for 120 Days on average.
| LYFT | SNN | |
|---|---|---|
Market Cap | $6.11B | $11.10B |
Volume | 13,504,560 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $24.57 | $37.17 |
52-Week Low | $12.65 | $26.42 |
Typical Hold Time | 47 Days | 120 Days |
Enterprise Value | $5.57B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $15.60, down 1.02% with a bullish technical signal despite recent earnings misses. The company shows strong fundamental improvement with revenue growing from $4.1B in 2022 to $6.3B in 2025 and achieving profitability with $2.84B net income. Recent developments include European expansion and a $272.5M legal settlement. Valuation metrics appear attractive with P/E of 2.27 and P/S of 0.93, though EV/EBITDA remains elevated at 33.28.
Lyft presents a mixed outlook with strong cash flow growth and expanding operations balanced against competitive pressures and regulatory risks. The stock trades below analyst consensus target of $18.07, offering potential upside, but faces headwinds from driver classification lawsuits and market saturation concerns. Execution on European expansion and sustained profitability will be key catalysts for further appreciation.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
